Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
Zach Reitano, CEO of Ro, discusses how GLP-1 drugs are revolutionizing healthcare by empowering patients as customers, details Ro's transformation from a struggling $5B unicorn to a $3B revenue company with 30% fewer employees, and argues that healthcare spending should increase as a percentage of GDP while fundamentally restructuring how care is delivered.
Summary
Zach Reitano presents a contrarian view that US healthcare spending should be as high as possible—potentially 50% of GDP or more—arguing that health is the most important thing society can spend money on. The problem isn't the percentage of GDP spent, but the cost per unit and lack of value received. He contrasts the US healthcare system's high prices with better outcomes in acute care (higher cancer survival rates, better stroke outcomes) compared to other OECD countries, noting that the real issue is chronic disease and lifestyle-related mortality.
Reitano identifies the central flaw in US healthcare: the patient is not the customer. Because individuals pay through taxes and suppressed wages rather than directly at point of purchase, misaligned incentives emerge. He cites LASIK, cosmetic surgery, and GLP-1 drugs as examples where direct-to-consumer cash pay creates transparency, lower prices, and better outcomes. When patients regained control of GLP-1 purchasing through direct-to-consumer channels, prices dropped from $1,300 to $149 while manufacturers increased profits through volume.
Ro's business model demonstrates this principle: it's built as a vertically integrated, custom-built software platform combining EMR, labs, pharmacies, and provider networks. The company serves four main categories—GLP-1s (fastest growing), cardiometabolic health, sexual health, dermatology, and fertility. In four years, Ro grew from $250M to $3B+ in run rate with fewer employees, riding the GLP-1 wave but outperforming competitors through continuous innovation and patient-centric focus.
Reitano describes a painful but transformative refounding in summer 2022 after the company had become a "zombie company"—growing slowly but burning money despite $500M in funding. He identified that the company had confused long-term vision with near-term strategy, hired too many people, and lost cultural coherence. He moved 7 VPs in early 2022 and 20% of the organization by June, intentionally creating a "strong attract, strong repel" culture with explicit values and a homogeneous way of working despite heterogeneous backgrounds.
Key operational changes included: daily steering meetings at 8:50 AM for two years to ensure accountability and alignment, eliminating long-term roadmaps in favor of 6-month planning with short-term precision, and sequential rather than parallel project execution. These changes, combined with hiring top talent and maintaining focus, enabled 10x business growth with 30% fewer people.
On the societal impact of GLP-1s, Reitano predicts 50%+ of Americans will eventually use these medications, comparing them to statins but with broader efficacy. He argues they're rewriting the healthcare system because large numbers of buyers suddenly care about one thing (metabolic health), and they're fundamentally changing incentives around employer-provided insurance and patient choice.
Reitano frames his approach through personal context: his father's influence as a doctor who saved his life and invested in his health outcomes (growth hormone for height, heart surgery, medication management) set him on a different trajectory. He sees Ro as recreating his father's individualized care approach at scale through software, motivated by the belief that better health unlocks human potential at both individual and societal levels.
On controversial topics, Reitano argues that jobs should never be prioritized over lives (using autonomous vehicles as an example where safety improvements are being delayed for job protection reasons), and that medicine must earn its place through outcomes rather than inputs. He critiques the stigma around preventive medications while society freely permits alcohol and other substances, arguing the inconsistency reveals deeper biases about weight, sexuality, and control.
Marketing strategy leverages authentic celebrity ambassadors (Charles Barkley, Serena Williams, Megan Fox) who genuinely use the products, focusing on creating "permission structures" for stigmatized health issues. Reitano emphasizes that Ro has always been willing to be misunderstood in service of patient outcomes, citing early criticism of "restaurant menu medicine" as actually a compliment—patients benefit from transparency and choice.
Final reflections include the importance of spousal support (his wife Cleo, who is a prominent YouTube educational creator), authentic love expressed regularly to family and colleagues, and the observation that the most significant societal progress comes from attacking upstream causes of death (infectious disease, maternal mortality leading to industrial revolution) rather than downstream treatments. He envisions healthcare becoming accessible at Netflix-like pricing through AI-enabled specialist-level care delivered directly to consumers.
About this episode
My guest today is Zach Reitano, the co-founder and CEO of Ro, the country’s leading provider of GLP-1s. In four years, Ro has grown from a $250 million run rate to over $3 billion, with fewer people than it had in 2021. The heart of our conversation is what he sees as the central flaw in American healthcare, which is that the patient is not the customer. He points to GLP-1s and LASIK as examples of what’s possible when patients pay directly, and he thinks AI could bring healthcare down to the price of a Netflix subscription. But to capture that opportunity, Zach first had to rebuild Ro's culture around high performance and a big heart. It shows in the stories Ro shares from people like Serena Williams, which help patients get past the stigma of seeking treatment. The inspiration behind it all is his father, a doctor whose care Zach wants to recreate in software. Please enjoy my conversation with Zach Reitano. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at colossus.com/subscribe. ----- Ramp’s mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to ramp.com/invest to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, Vanta continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Invest Like the Best listeners get a special offer of $1,000 off Vanta when you go to vanta.com/invest. ----- WorkOS is the infrastructure B2B and AI-native companies use to sell to enterprise. It covers everything enterprise security requires: SSO, SCIM, RBAC, Audit Logs, AI governance, and more. Trusted by 2,000+ fast-growing companies, including OpenAI, Anthropic, Cursor, and Vercel. ----- Rogo is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit ridgeline.ai. ----- Editing and post-production work for this episode was provided by The Podcast Consultant. Timestamps: (00:01:35) Why Healthcare Spending Should Rise (00:05:39) Putting Patients in Control (00:10:37) Inside Ro's GLP-1 Business (00:16:29) How GLP-1s Could Reshape Society (00:23:15) The Hidden Cost of Protecting Jobs (00:28:35) Rebuilding a Zombie Company (00:36:33) What Drove Ro's 10x Growth (00:43:49) Where Healthcare Goes Next (00:46:27) Zach's Personal Health Stack (00:54:07) Finding the Work You Were Born For (01:00:15) Ro's Consumer Playbook (01:04:39) Breaking Medical Taboos (01:12:54) The Kindest Thing
Key Insights
- Reitano argues the US healthcare system's problem isn't that it spends 18% of GDP on healthcare, but that the cost per unit is rising while value is unclear, and that healthcare spending should potentially reach 50% or higher if it delivered better outcomes.
- He contends that the fundamental flaw in US healthcare is that patients are not the customer at point of purchase, since individuals pay through taxes and suppressed wages rather than directly, creating misaligned incentives between patients and providers.
- GLP-1 drugs demonstrate that when patients become direct purchasers, prices fall dramatically (from $1,300 to $149) while manufacturers increase profits through volume, proving that transparency and direct payment align incentives.
- Reitano built Ro as a fully vertically integrated platform combining custom EMR, labs, pharmacies, and provider networks specifically to eliminate middlemen and give patients direct control, viewing integration as essential to patient-centric care.
- He describes how Ro transformed from a struggling zombie company (growing 9% with $500M raised at $5B valuation) to a $3B revenue business by refounding in 2022 with ruthless focus on culture and sequential execution rather than trying to do everything simultaneously.
- Reitano implemented daily 8:50 AM steering meetings for two years to create impossible-to-miss accountability, finding that weekly planning windows allow too much context switching and competing priorities, while daily alignment forces execution.
- He argues that long-term roadmaps in fast-moving industries like healthcare and AI are 'false precision' similar to printing MapQuest instead of using Google Maps, and that organizations benefit from rigid 6-month plans with flexibility beyond.
- Reitano predicts 50%+ of Americans will eventually take GLP-1 medications prophylactically for metabolic health and disease prevention, comparing them to statins in ubiquity but with broader clinical applications across diabetes, heart disease, kidney disease, liver disease, and neurodegeneration.
- He believes that prioritizing jobs over lives (such as delaying autonomous vehicle deployment despite proven safety improvements) should carry a 'body count' attributed to those opposing the technology, viewing it as moral equivalent to preventing lifesaving treatments.
- Reitano observes that society tolerates alcohol (literal poison) but obsesses over whether people should take medications with established randomized controlled trials and expert oversight, revealing hypocrisy in how risks and benefits are evaluated.
- He credits his father's willingness to fight the healthcare system on his behalf (obtaining growth hormone treatment, navigating cardiac care) as transforming his life trajectory, and sees Ro as extending that individualized advocacy to millions through software and operations.
- Reitano argues that celebrity marketing effectiveness comes from authenticity and permission structures rather than production value, since AI now makes visually polished ads cheap, making recognizable faces the remaining scarce resource to break through noise.
Topics
Transcript
Ramp is the only platform built to make your finance team leaner, faster, and better, saving businesses 5% annually on average so you can stay focused on growth. Ramp customers grow 3.2 times faster than the average American business. Visa, Purcell, Cursor, Stripe, and 70,000 other businesses all run on Ramp. Mine does too, and so should yours. Learn more at ramp.com. Rogo is the AI platform purpose-built for financial institutions, serving tens of thousands of bankers and investors at hundreds of leading firms worldwide. Rogo's AI agents autonomously execute large chunk of your firm's workflows. They can screen deals, draft sims, run buyer outreach, and do diligence on data rooms, all with full security and compliance handled. Every action…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Invest Like the Best with Patrick O'Shaughnessy
Brad Gerstner & Geoffrey Canada - Raising the Floor for Every American Child - [Invest Like the Best, EP.501]
Brad Gerstner and Geoffrey Canada discuss the Invest America Act, which creates universal capital accounts for all American children starting with $1,000 at birth, designed to address wealth inequality and restore faith in capitalism by ensuring every child has access to investment growth and compound wealth building.
Ramtin Naimi - The State of Venture - [Invest Like the Best, EP.499]
Ramtin Naimi discusses the current state of venture capital markets, characterizing them as extremely fast-paced with unprecedented opportunity but moderate frothiness compared to 2021. He analyzes deal structures, LP capital constraints, compute needs for AI companies, and identifies companies like Isomorphic Labs, Physical Intelligence, and Applied Compute as bellwether businesses for the next five years.
Noah Shinn - Building Instinct: The Personal Agent - [Invest Like the Best, EP.493]
Noah Shinn, CEO of Instinct, discusses building a personal AI agent that acts autonomously on behalf of users through natural communication channels like text, email, and voice calls. The company is growing at 10% daily with over $1 billion in transaction volume, and Shinn explores how personal agents will fundamentally transform digital commerce, business operations, and user interaction with technology.
Gabe Stengel - Building Investing Superintelligence - [Invest Like the Best, EP.492]
Gabe Stengel, founder of Rogo, discusses building AI-powered investment intelligence tools for financial professionals. He explains how rapidly improving AI models are enabling automation of complex financial workflows, the challenges of enterprise sales in finance, and his vision for transforming capital markets through AI infrastructure.
Michael Moritz - Lessons From 40 Years of Investing and Writing - [Invest Like the Best, EP.491]
Michael Moritz reflects on 40 years of investing and writing, exploring how family history shaped his character, the importance of identifying exceptional founders through their early life experiences, and lessons learned from building Sequoia Capital into an enduring institution.